N
NovaBay Pharmaceuticals Inc
XBER:B9P
NovaBay Pharmaceuticals Inc
XBER:B9P
Price:
0.114
EUR
-11.63%
Market Closed
Market Cap:
€480.5k
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
N
|
NovaBay Pharmaceuticals Inc
XBER:B9P
|
US |
|
STM Group PLC
LSE:STM
|
IM |
|
Naipu Mining Machinery Co Ltd
SZSE:300818
|
CN |
|
T
|
Tianjin Tianyao Pharmaceuticals Co Ltd
SSE:600488
|
CN |
|
Z
|
Zhejiang Kaier New Materials Co Ltd
SZSE:300234
|
CN |
|
W
|
Wee Hur Holdings Ltd
SGX:E3B
|
SG |
|
Macquarie Group Ltd
ASX:MQG
|
AU |
|
N
|
NSL Foods PCL
SET:NSL
|
TH |
|
E
|
Euwax AG
F:EUX
|
DE |
|
Z
|
Zhuhai Port Co Ltd
SZSE:000507
|
CN |
|
J
|
Jiangyin Hengrun Heavy Industries Co Ltd
SSE:603985
|
CN |
|
Yangzhou Chenhua New Material Co Ltd
SZSE:300610
|
CN |
Multiples-Based Value
There is not enough data to reliably calculate the multiples-based value of B9P.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
B9P
Multiples-Based Value
Base Case
Not Available
Multiples Across Competitors
B9P Competitors Multiples
NovaBay Pharmaceuticals Inc Competitors
NovaBay Pharmaceuticals Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
N
|
NovaBay Pharmaceuticals Inc
XBER:B9P
|
480.5k EUR | 0 | -0 | 0 | 0 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
829.8B USD | 12.7 | 40.2 | 27.2 | 29 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
579B USD | 6.1 | 21.6 | 15 | 18.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4 | 19.3 | 11.5 | 12.9 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
296B USD | 4.6 | 16.2 | 10 | 12.2 | |
| CH |
|
Novartis AG
SIX:NOVN
|
229.3B CHF | 5.2 | 21.1 | 13 | 16.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
214.5B GBP | 5.1 | 29.1 | 16.1 | 22.7 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD | 102.3 | -81.1 | 375.3 | 941.3 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1T DKK | 3.3 | 9.8 | 7.3 | 8.6 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.7B USD | 2.5 | 19.8 | 7.6 | 10.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
117.8B USD | 2.4 | 16.7 | 7.1 | 8.7 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
